Crossfire Oncology
1 known investors
Find your way into Crossfire Oncology
Crossfire Oncology develops kinase inhibitors, degraders, and degrader antibody conjugates targeting cancer and other cellular proliferation disorders using proprietary EPriL chemistry. The company serves oncology markets with a pipeline including BAL0891, a clinical-stage dual TTK/PLK1 inhibitor.
Investors · 1
Frequently asked questions
- What does Crossfire Oncology do?
- Crossfire Oncology develops kinase inhibitors, degraders, and degrader antibody conjugates targeting cancer and other cellular proliferation disorders using proprietary EPriL chemistry. The company serves oncology markets with a pipeline including BAL0891, a clinical-stage dual TTK/PLK1 inhibitor.
- Who are Crossfire Oncology's investors?
- Crossfire Oncology's investors include BOM.